Roivant Wins FDA Approval for LISRAYA in Dermatomyositis
Basel, Switzerland, London, United Kingdom & New York – August 27, 2026 Roivant announced that the U.S. Food and...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
Basel, Switzerland, London, United Kingdom & New York – August 27, 2026 Roivant announced that the U.S. Food and...
Hong Kong, Shanghai & Florham Park, New Jersey – August 28, 2026 HUTCHMED announced that China’s National Medical Products...
